An economic model of long-term use of celecoxib in patients with osteoarthritis

par Loyd, Michael, Rublee, Dale, Jacobs, Philip
Publié 2007

The association of comorbidities, utilization and costs for patients identified with low back pain

par Ritzwoller, Debra P, Crounse, Laurie, Shetterly, Susan, Rublee, Dale
Publié 2006

Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial [ISRCTN22931023]

par Rublee, Dale, Opal, Steven M, Schramm, Wolfgang, Keinecke, Heinz-Otto, Knaub, Sigurd
Publié 2002

Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences

par Lanitis, Tereza, Leipold, Robert, Hamilton, Melissa, Rublee, Dale, Quon, Peter, Browne, Chantelle, Cohen, Alexander T.
Publié dans BMC Health Serv Res (2017)

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation

par Dorian, Paul, Kongnakorn, Thitima, Phatak, Hemant, Rublee, Dale A., Kuznik, Andreas, Lanitis, Tereza, Liu, Larry Z., Iloeje, Uchenna, Hernandez, Luis, Lip, Gregory Y.H.
Publié 2014

Reverse Engineering and Evaluation of Prediction Models for Progression to Type 2 Diabetes: An Application of Machine Learning Using Electronic Health Records

par Anderson, Jeffrey P., Parikh, Jignesh R., Shenfeld, Daniel K., Ivanov, Vladimir, Marks, Casey, Church, Bruce W., Laramie, Jason M., Mardekian, Jack, Piper, Beth Anne, Willke, Richard J., Rublee, Dale A.
Publié dans J Diabetes Sci Technol (2015)